顺铂联合培美曲塞二钠治疗晚期NSCLC的临床疗效观察

目的 观察顺铂联合培美曲塞二钠用于晚期非小细胞肺癌（NSCLC）的临床疗效,探讨其不良反应.方法 选择晚期NSCLC患者共90例,依照随机数字表法将其随机分两组,A组（n=30）采用＂顺铂＋培美曲塞二钠＂治疗方案,B组（n=60）采用＂顺铂＋吉西他滨＂治疗方案;对比分析两组NSCLC患者的临床疗效.结果 两组在临床疗效方面的差异不显著（P＞0.05）,不具有统计学意义;A组的血液学、消化道、生化学毒性要显著优于B组（P＜0.05）,具有统计学意义.结论 顺铂联合＋培美曲塞二钠治疗晚期NSCLC疗效稳定,毒性更低,耐受性更佳.

Observation on clinical curative effect of cisplatin and pemetrexed disodium in the treatment of patients with advanced non-small cell lung cancer

Objective To observe the clinical effect of cisplatin and pemetrexed disodium in the treatment of patients with ad- vanced non small cell lung cancer （NSCLC）. Methods 90 patients with advanced NSCLC were randomly divided into 2 groups. The group A （n = 30） was treated with cisplatin and pemetrexed disodium, and the group B （n = 60） was treated with cisplatin plus gemcit- abine. The clinical curative effect of the two groups was compared and analyzed. Results There was no significant difference on clinical efficacy between the two groups （ P 〉 0. 05 ）. Hematology and gastrointestinal biochemical toxicity was significantly lower in the group A than in the group B （P 〈 0. 05 ）. Conclusion Cisplatin and pemetrexed disodium has the advantages of lower toxicity, good tolerability and stable efficacy in the treatment of patients with advanced NSCLC.